Display options
Cite
Xie Y, Collins WJ, Audeh MW, et al. Breast Cancer Survivorship and Cardiovascular Disease: Emerging Approaches in Cardio-Oncology. Curr Treat Options Cardiovasc Med. 2015;17(12):60doi: 10.1007/s11936-015-0421-y.
Xie, Y., Collins, W. J., Audeh, M. W., Shiao, S. L., Gottlieb, R. A., Goodman, M. T., Merz, C. N., & Mehta, P. K. (2015). Breast Cancer Survivorship and Cardiovascular Disease: Emerging Approaches in Cardio-Oncology. Current treatment options in cardiovascular medicine, 17(12), 60. https://doi.org/10.1007/s11936-015-0421-y
Xie, Yu, et al. "Breast Cancer Survivorship and Cardiovascular Disease: Emerging Approaches in Cardio-Oncology." Current treatment options in cardiovascular medicine vol. 17,12 (2015): 60. doi: https://doi.org/10.1007/s11936-015-0421-y
Xie Y, Collins WJ, Audeh MW, Shiao SL, Gottlieb RA, Goodman MT, Merz CN, Mehta PK. Breast Cancer Survivorship and Cardiovascular Disease: Emerging Approaches in Cardio-Oncology. Curr Treat Options Cardiovasc Med. 2015 Dec;17(12):60. doi: 10.1007/s11936-015-0421-y. PMID: 26490280; PMCID: PMC6364685.
Copy Download .nbib Format: NLM
Share it on

Curr Treat Options Cardiovasc Med. 2015 Dec;17(12):60. doi: 10.1007/s11936-015-0421-y.

Breast Cancer Survivorship and Cardiovascular Disease: Emerging Approaches in Cardio-Oncology.

Current treatment options in cardiovascular medicine

Yu Xie, William J Collins, M William Audeh, Stephen L Shiao, Roberta A Gottlieb, Marc T Goodman, C Noel Bairey Merz, Puja K Mehta

Affiliations

  1. Cedars-Sinai Heart Institute, Barbra Streisand Women's Heart Center, 127 S. San Vicente Blvd, A3212, Los Angeles, CA, 90048, USA.
  2. Inpatient Specialty Program, Cedars-Sinai Heart Institute, Barbra Streisand Women's Heart Center, Los Angeles, CA, USA.
  3. Wasserman Breast Cancer Risk Reduction Program, Samuel Oschin Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
  4. Department of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
  5. Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
  6. Cedars-Sinai Heart Institute, Barbra Streisand Women's Heart Center, 127 S. San Vicente Blvd, A3212, Los Angeles, CA, 90048, USA. [email protected].

PMID: 26490280 PMCID: PMC6364685 DOI: 10.1007/s11936-015-0421-y

Abstract

OPINION STATEMENT: Cardiovascular disease (CVD) and breast cancer cause substantial morbidity and mortality in women and are major public health concerns in the USA. While aggressive screening and targeted, advanced treatment for breast cancer have had a measurable impact on breast cancer survival, treatment is not without significant cardiotoxic effects. Anthracycline-based chemotherapy can lead to left ventricular dysfunction and failure, as well as a decline in exercise tolerance and cardio-pulmonary reserve despite preserved ejection fraction. Trastuzumab, a newer monoclonal antibody targeting the Her2 receptor used in the treatment of Her2+ cancer, is also linked to left ventricular dysfunction, although the long-term cardiac effects are presently unclear. Radiation treatment particularly for left-sided breast cancer has been associated with increased rates of ischemic heart disease. As women have increasing survival and cure rates from early breast cancer, long-term consequences on the heart that are secondary to therapy are a major concern. These need to be identified, treated, and avoided when possible. Further research and clear surveillance guidelines are needed to aid the practicing clinician in CVD prevention in breast cancer survivors.

Keywords: Breast cancer; Cardio-oncology; Cardiotoxicity; Heart failure

References

  1. Cancer Treat Rep. 1976 Sep;60(9):1281-4 - PubMed
  2. Life Sci. 1999;65(12):1265-74 - PubMed
  3. J Am Diet Assoc. 1999 Oct;99(10):1212-21 - PubMed
  4. N Engl J Med. 2000 Apr 13;342(15):1077-84 - PubMed
  5. J Pharmacol Exp Ther. 2000 Jul;294(1):396-401 - PubMed
  6. J Am Coll Cardiol. 2000 Aug;36(2):517-22 - PubMed
  7. Med Sci Monit. 2000 Mar-Apr;6(2):411-20 - PubMed
  8. Cardiovasc Drug Rev. 2001 Summer;19(2):152-71 - PubMed
  9. J Clin Oncol. 2002 Mar 1;20(5):1215-21 - PubMed
  10. Mol Cell Biochem. 2002 May-Jun;234-235(1-2):119-24 - PubMed
  11. Toxicol Appl Pharmacol. 2002 Dec 15;185(3):218-27 - PubMed
  12. Cancer. 2003 Apr 1;97(7):1746-57 - PubMed
  13. Circulation. 2003 Sep 30;108(13):1554-9 - PubMed
  14. Oncol Rep. 2004 Feb;11(2):505-8 - PubMed
  15. Am J Cardiol. 2004 May 6;93(9A):3B-6B - PubMed
  16. J Mol Cell Cardiol. 2004 Oct;37(4):837-46 - PubMed
  17. J Clin Oncol. 2005 May 1;23(13):2900-2 - PubMed
  18. Circulation. 2005 Sep 20;112(12):e154-235 - PubMed
  19. Lancet Oncol. 2005 Nov;6(11):886-98 - PubMed
  20. J Clin Oncol. 2005 Nov 1;23(31):7811-9 - PubMed
  21. J Am Soc Echocardiogr. 2005 Dec;18(12):1440-63 - PubMed
  22. J Clin Oncol. 2006 Sep 1;24(25):4100-6 - PubMed
  23. Circulation. 2006 Dec 5;114(23):2474-81 - PubMed
  24. J Am Coll Cardiol. 2006 Dec 5;48(11):2258-62 - PubMed
  25. Circulation. 2007 Aug 28;116(9):1081-93 - PubMed
  26. Cancer. 2007 Oct 15;110(8):1840-50 - PubMed
  27. J Am Coll Cardiol. 2007 Oct 9;50(15):1435-41 - PubMed
  28. J Mol Cell Cardiol. 2009 Nov;47(5):698-705 - PubMed
  29. Circulation. 2010 Feb 9;121(5):675-83 - PubMed
  30. Eur J Heart Fail. 2011 Jan;13(1):1-10 - PubMed
  31. Breast Cancer Res. 2011 Jun 20;13(3):R64 - PubMed
  32. BMC Cancer. 2011 Jul 27;11:318 - PubMed
  33. Cell Death Dis. 2011 Aug 11;2:e190 - PubMed
  34. Biomarkers. 2011 Sep;16(6):457-65 - PubMed
  35. J Am Coll Cardiol. 2011 Aug 23;58(9):988-9 - PubMed
  36. FASEB J. 1990 Oct;4(13):3076-86 - PubMed
  37. J Clin Oncol. 2012 Feb 1;30(4):380-6 - PubMed
  38. J Rheumatol. 2012 Feb;39(2):448-50 - PubMed
  39. Am Heart J. 2012 Feb;163(2):156-63 - PubMed
  40. J Clin Med Res. 2009 Apr;1(1):8-12 - PubMed
  41. Cochrane Database Syst Rev. 2012 Apr 18;(4):CD006243 - PubMed
  42. Int J Cardiol. 2013 Sep 1;167(5):2306-10 - PubMed
  43. Eur J Heart Fail. 2012 Aug;14(8):803-69 - PubMed
  44. Cochrane Database Syst Rev. 2012 Aug 15;(8):CD008465 - PubMed
  45. J Natl Cancer Inst. 2012 Sep 5;104(17):1293-305 - PubMed
  46. Ann Oncol. 2012 Oct;23 Suppl 7:vii155-66 - PubMed
  47. Int J Radiat Oncol Biol Phys. 2013 Mar 15;85(4):959-64 - PubMed
  48. Cardiovasc Res. 2013 Jan 1;97(1):77-87 - PubMed
  49. J Clin Oncol. 2012 Dec 20;30(36):4458-61 - PubMed
  50. Nat Med. 2012 Nov;18(11):1639-42 - PubMed
  51. J Am Coll Cardiol. 2012 Dec 11;60(23):2384-90 - PubMed
  52. Cardiology. 2012;123(4):240-7 - PubMed
  53. J Am Soc Echocardiogr. 2013 Feb;26(2):185-91 - PubMed
  54. J Am Coll Cardiol. 2013 Jan 22;61(3):267-74 - PubMed
  55. N Engl J Med. 2013 Mar 14;368(11):987-98 - PubMed
  56. J Am Coll Cardiol. 2013 Oct 15;62(16):e147-239 - PubMed
  57. Circulation. 2014 Jun 24;129(25 Suppl 2):S49-73 - PubMed
  58. J Am Coll Cardiol. 2014 Mar 4;63(8):809-16 - PubMed
  59. J Am Heart Assoc. 2014 Feb 28;3(1):e000472 - PubMed
  60. Am Heart J. 2014 Sep;168(3):317-324.e1 - PubMed
  61. Eur Heart J Cardiovasc Imaging. 2014 Oct;15(10):1063-93 - PubMed
  62. Eur J Heart Fail. 2015 Jan;17(1):81-9 - PubMed
  63. Can J Cardiol. 2015 Mar;31(3):302-7 - PubMed
  64. Cancer Treat Rev. 2015 Jun;41(6):554-67 - PubMed
  65. Circulation. 2015 Jun 2;131(22):1981-8 - PubMed
  66. Intern Emerg Med. 2016 Mar;11(2):183-9 - PubMed
  67. Clin Biochem. 2015 Aug;48(12):749-50 - PubMed
  68. Springerplus. 2015 Aug 01;4:388 - PubMed
  69. Eur Cardiol. 2015 Jul;10(1):19-24 - PubMed
  70. Cancer. 1967 Mar;20(3):333-53 - PubMed
  71. J Cancer Res Clin Oncol. 1983;106(2):136-42 - PubMed
  72. J Clin Oncol. 1984 Feb;2(2):112-7 - PubMed
  73. JAMA. 1978 Oct 6;240(15):1603-6 - PubMed
  74. N Engl J Med. 1979 Feb 8;300(6):278-83 - PubMed
  75. Fundam Appl Toxicol. 1997 Jul;38(1):23-37 - PubMed

Publication Types

Grant support